Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report

Figure 8 The serial changes of urine protein-to-creatinine ratio and thyroglobulin is pictured. A: Lenvatinib, 10 mg/d; B: The first month of sorafenib; C: The second month of sorafenib; D: The third month of sorafenib; E: The fourth month of sorafenib; F: The fifth month of sorafenib; Therapeutic response is proved by drops of thyroglobulin, and urine protein-to-creatinine ratio is strongly relative to therapeutic response (Pearson correlation coefficient: 0.94; R²: 0.88; adjusted R²: 0.85).